A Phase IV, Randomized, Multi-Center, Open-Label, Prospective, Crossover Study to Evaluate Patient Preference of Movantik™ Versus Polyethylene Glycol 3350 for Opioid-Induced Constipation (OIC) Treatment
Phase of Trial: Phase IV
Latest Information Update: 12 Sep 2017
At a glance
- Drugs Naloxegol (Primary) ; PEG 3350 (Primary)
- Indications Constipation
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 07 Sep 2017 Status changed from recruiting to completed.
- 26 Jul 2017 Planned End Date changed from 22 Jan 2018 to 29 Aug 2018.
- 26 Jul 2017 Planned primary completion date changed from 22 Jan 2018 to 29 Aug 2018.